SHR-2554
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for SHR-2554, covering 2025-12-31 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma [Phase 2]